On Monday, Shares of Apple Inc. (NASDAQ:AAPL), lost -1.39% to $122.77.
Apple declared financial results for its fiscal 2015 third quarter ended June 27, 2015. The Company posted quarterly revenue of $49.6 billion and quarterly net profit of $10.7 billion, or $1.85 per diluted share. These results compare to revenue of $37.4 billion and net profit of $7.7 billion, or $1.28 per diluted share, in the year-ago quarter. Gross margin was 39.7 percent contrast to 39.4 percent in the year-ago quarter. International sales accounted for 64 percent of the quarter’s revenue.
Apple is providing the following guidance for its fiscal 2015 fourth quarter:
- revenue between $49 billion and $51 billion
- gross margin between 38.5 percent and 39.5 percent
- operating expenses between $5.85 billion and $5.95 billion
- other income/(expense) of $400 million
- tax rate of 26.3 percent.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Biogen Inc. (NASDAQ:BIIB), inclined 3.13% to $309.43, during its last trading session.
Biogen and the Parkinson’s Institute and Clinical Center declared the formation of a planned alliance focused on enhancing the understanding of the underlying biology of Parkinson’s disease (PD) and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogen’s focus on neurodegenerative disease and approach to clinical development.
The multi-year partnership comprises an array of PD-related activities designed to drive advances in basic science and treatment counting:
- Discovery of gene targets and modifier genes that might serve as novel therapeutic targets
- The creation of well-defined patient-derived induced pluripotent stem cells (iPSC)
- A study of gastrointestinal symptoms related to PD
- A search for quantitative and symptom-based trial endpoints
- The potential identification of new therapeutic approval pathways.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease.
Finally, Gold Fields Ltd. (NYSE:GFI), ended its last trade with -1.37% loss, and closed at $2.88, despite Gold prices rose on Monday, nudging upward from a five-year low, after a steep drop in Chinese equities spurred some investors to buy the precious metal as a hedge.
The most actively traded gold futures contract, for August delivery, rose $10.90, or 1%, to settle at $1,096.40 a troy ounce on the Comex division of the New York Mercantile Exchange. The contract had fallen to a five-year low of $1,085.50 an ounce on Friday, according to WSJ.
Gold Fields Limited operates as a gold mining company. The company engages in the exploration, extraction, processing, and smelting of gold and copper properties. It holds interests in eight operating mines in South Africa, Ghana, Australia, and Peru.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
